Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) Following Allogenic Hematopoietic Stem Cell Transplantation (HSCT)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Kelli Cole
- Phone Number: 516-734-8973
- Email: kcole5@northwell.edu
Study Contact Backup
- Name: Angie Fleury
- Phone Number: 516-734-8973
- Email: AFleury2@northwell.edu
Study Locations
-
-
New York
-
New Hyde Park, New York, United States, 10016
- Recruiting
- Northwell Health
-
Contact:
- Kelli Cole
- Phone Number: 516-734-8973
- Email: kcole5@northwell.edu
-
Contact:
- Angie Fleury
- Phone Number: 516-734-8973
- Email: AFleury2@northwell.edu
-
Principal Investigator:
- A. Samer Al-Homsi, MD, MBA
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥14 years
- Karnofsky score ≥70%
- No evidence of progressive bacterial, viral, or fungal infection
- Creatinine clearance >50 mL/min/1.72m2
- ALT and AST <3 x the upper limit of normal
- Total bilirubin <2 x the upper limit of normal (except for Gilbert's syndrome)
- Alkaline phosphatase ≤250 IU/L
- Left Ventricular Ejection Fraction (LVEF) >45%
- Adjusted Carbon Monoxide Diffusing Capacity (DLCO) >50%
- Negative HIV serology
- Negative pregnancy test: Confirmation per negative serum β-human chorionic gonadotropin (β-hCG)
- Willing to comply with all study procedures and be available for the duration of the study.
Exclusion Criteria:
- Pregnant or nursing females or women of reproductive capability who are unwilling to completely abstain from heterosexual sex or practice 2 effective methods of contraception from start of conditioning through 90 days after the last dose of study drug. A woman of reproductive capability is one who has not undergone a hysterectomy (removal of the womb), has not had both ovaries removed, or has not been post-menopausal (stopped menstrual periods) for more than 24 months in a row.
- Male subjects who refuse to practice effective barrier contraception from the start of conditioning through a minimum of 90 days after the last dose of study drug, or completely abstain from heterosexual intercourse. This must be done even if they are surgically sterilized (i.e., post-vasectomy).
- Inability to provide informed consent.
- Patient had myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see Appendix D), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant.
- Known allergies to any of the components of the investigational treatment regimen.
- Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
- Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma, an in-situ malignancy, or low-risk prostate cancer after curative therapy.
- Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial.
- Prisoners
- Pregnant women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Participants with hematological malignancies
Participants undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) will receive a combination of cyclophosphamide, known commercially as Cytoxan®, abatacept, known as Orecia® and bortezomib commercially known as Velcade®, to reduce the rate of graft-versus-host disease (GvHD).
These medications will be given for GvHD prevention during the transplant process.
|
1.3 mg/m2 IV 6 hours after graft infusion completion and 72 hours thereafter.
Other Names:
37.5 mg/kg IV over 1 hour on Day +3 and +4
Other Names:
Dose level 0: 10 mg/kg IV over 30-60 minutes on day +5 Dose level 1: 10mg/kg IV over 30-60 minutes on day +5 and +14 Dose level 2: 10mg/kg IV over 30-60 minutes on day +5, +14, and +28
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Phase I:Incidence Dose limiting toxicity (DLT)
Time Frame: Day+1 to Day +120
|
Defined as grade 4 non-hematologic toxicity affecting the oral cavity, gastrointestinal tract, lung, heart, liver, kidney, bladder, or central nervous system.
|
Day+1 to Day +120
|
|
Phase II: Grades II-IV Acute GvHD
Time Frame: Day+1 to Day +120
|
The first day of grades II-IV acute GvHD will be recorded for that grade.
This end point will be evaluated through day +120 post-transplant.
|
Day+1 to Day +120
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Chronic GvHD
Time Frame: Day +1 to Day +365
|
The diagnosis of chronic GvHD is based on clinical and pathological evaluation by the principal investigator in collaboration with the treating physician.The analysis will be based on the maximum grade of chronic GvHD
|
Day +1 to Day +365
|
|
Primary graft failure
Time Frame: Day +1 to Day +30
|
Incidence of graft failure will be calculated from date of transplant to failure for all subjects who receive a transplant and any prophylactic treatment and from date of completion of prophylactic treatment for all participants that completed treatment
|
Day +1 to Day +30
|
|
Poor graft function
Time Frame: Day +1 to Day +30
|
Incidence of poor graft function will be calculated, from date of transplant to failure for all subjects who receive a transplant and any prophylactic treatment and from date of completion of prophylactic treatment for all participants that completed treatment
|
Day +1 to Day +30
|
|
Secondary graft failure
Time Frame: Day +1
|
Evaluated after engraftment is achieved will be calculated from date of engraftment for all subjects with engraftment
|
Day +1
|
|
Treatment-related mortality (TRM)
Time Frame: Day +1 to Day +730
|
Analyzed based on participants that who received a transplant with any prophylactic treatment and for all subjects who received a transplant and completed prophylactic treatment.
|
Day +1 to Day +730
|
|
Relapse rate (RR)
Time Frame: Day +1 to Day +730
|
Evaluated to day +730 and will be analyzed for all subjects who received a transplant and for all transplanted subjects that completed treatment
|
Day +1 to Day +730
|
|
GvHD and relapse-free survival (GRFS)
Time Frame: Day +1 to Day +730
|
Evaluated to day +730 and considers as successes participants that are without reported GvHD III-IV acute GvHD, chronic GvHD requiring systemic therapy and have not experienced relapse or death after transplant
|
Day +1 to Day +730
|
|
Overall survival (OS)
Time Frame: Day +1 to Day +730
|
Evaluated to day +730 and considers all participants who received a transplant and for all transplanted subjects who completed prophylactic treatment
|
Day +1 to Day +730
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: A. Samer Al-Homsi, MD, MBA, Northwell Health
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Graft vs Host Disease
- Immunoconjugates
- Amino Acids, Peptides, and Proteins
- Proteins
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Hydrocarbons
- Antibodies
- Immunoglobulins
- Blood Proteins
- Serum Globulins
- Globulins
- Inorganic Chemicals
- Phosphoramide Mustards
- Nitrogen Mustard Compounds
- Mustard Compounds
- Hydrocarbons, Halogenated
- Phosphoramides
- Organophosphorus Compounds
- Boronic Acids
- Acids, Noncarboxylic
- Acids
- Boron Compounds
- Pyrazines
- Bortezomib
- Abatacept
- Cyclophosphamide
Other Study ID Numbers
Other Study ID Numbers
- 21-00797
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.